Philip Lindsell, managing director of Flarin, discusses the challenges of joint pain relief in an era of active living.
More than 12% of the population currently suffers from joint pain, which remains one of the most common reasons that patients seek advice from healthcare professionals. Whether associated with osteoarthritis, inflammatory conditions, injury, overuse or simply the physiological effects of ageing, joint pain places a substantial burden not only on individuals but also on the wider healthcare system.
As our population ages and expectations around mobility and independence increase, consumers are increasingly adopting an active living lifestyle, devoting more of their time to physical and indeed mental activity to improve their overall wellbeing. As a result, they can consider how their own pain management strategies can, through greater self-care, better support this positive lifestyle, enabling them to maintain mobility and remain socially engaged.
For many patients, joint pain is not simply a symptom but a barrier to participation in work, exercise, daily living and even restorative sleep. Poorly managed pain contributes to reduced physical activity, deconditioning, low mood and, in some cases, increased reliance on secondary care services. While some of this demand is unavoidable, a proportion relates to patients seeking reassurance or incremental adjustments to pain control that might be better managed through informed self-care.
Supporting informed self-care
This is where healthcare professionals play a pivotal role. Empowering patients to make appropriate over-the-counter (OTC) choices for mild to moderate joint pain can reduce avoidable appointments while maintaining safety and efficacy. However, empowerment must be underpinned by education. Patients are often influenced by marketing messages or anecdote rather than clear evidence. Guiding them towards evidence-based selection – including reviewing the Summary of Product Characteristics (SmPC) where appropriate – ensures decisions are made on a clear understanding of dosing and formulation characteristics.
Not all ibuprofen formulations, for example, are manufactured in the same way. Advances in measurement may yield additional data on their differing characteristics as treatments despite delivering the same active ingredient. For example, lipid-based formulations of ibuprofen are designed to dissolve the active ingredient in lipids. Lipids are absorbed in the small intestine and are used in other medicines to aid absorption.
For patients, efficacy matters, but so does how well a treatment is tolerated. These factors together shape not just the relief that patients experience but also their confidence in managing joint pain day to day. Gastrointestinal concerns remain one of the principal limitations of non-steroidal anti-inflammatory drug (NSAID) use, particularly in older adults who may already have comorbidities or be taking concomitant medications. While no NSAID is without risk, understanding formulation differences enables more nuanced patient conversations. Encouraging patients to read and understand product information – and guiding them through it where necessary – can support safer self-management and reduce inappropriate switching between products without clinical rationale.
Access and responsibility
The commercial availability of pain relief products has expanded significantly in recent years. Retail outlets such as supermarkets and pharmacies, together with online stores such as Amazon, now provide extensive availability, and patients frequently make their own choice of products rather than seeking advice. In the UK alone, pain relief products are widely accessible across high-street retailers as well as pharmacies. This accessibility has clear benefits in enabling consumers to manage their symptoms themselves and reduce pressure on GPs and the NHS. However, where consumers do seek advice from a GP or at a pharmacy, it also places greater responsibility on healthcare professionals to ensure patients understand what they are selecting and why.
Joint and muscular pain relief products account for a substantial proportion of OTC analgesics sales. Poorly managed musculoskeletal pain has broader repercussions, contributing to lost productivity, increased sickness absence and secondary complications associated with inactivity. At a time when healthcare systems are under intense financial and operational pressure, optimising management through self-care is not simply a clinical issue, it is a public health and economic imperative.
Safe and active living
Active living should be a shared goal across healthcare. Supporting patients to remain mobile and independent requires effective, accessible pain management strategies. This includes encouraging lifestyle interventions, which for some patients may include physiotherapy or even weight management, alongside pharmacological options where appropriate. OTC analgesics, when selected thoughtfully and used correctly, can form part of that toolkit.
For healthcare professionals, the challenge is balancing safety with accessibility. The challenge is to avoid both under-treatment, which drives repeated consultations and patient dissatisfaction, and over-reliance on systemic therapies where risks outweigh benefits. Clear guidance on duration of use, appropriate dosing and red-flag symptoms remains essential.
Structured, informed conversations about joint pain can make a real difference. When patients leave with clear, evidence-based guidance backed by reliable product information, the result is fewer unnecessary/trivial re-attendances and they become more confident in self-management.
Looking ahead
Looking ahead, the evidence around formulation science will continue to evolve, potentially offering a clearer basis of choice around such factors as improved tolerability and targeted effect. Evidence can then support education, transparency and professional guidance in responsible pain management.
Joint pain will continue to be one of the defining clinical challenges of an ageing population. Informed self-care, leveraging advances in the evidence around formulation science and maintaining a patient-centred approach, can reduce system burden while helping individuals remain active for longer.
In doing so, consumers can move closer to a sustainable healthcare model that supports active living and quality of life.
